Patent estate

Zydus Lifesciences — Patent Portfolio

1 drug with active patents · 3 active patents · 0 expired · 0 biologics with BPCIA exclusivity

AI-enriched 3/3 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2035

Patent estate by drug

Januvia (SITAGLIPTIN)

Cliff 2035 · 9y
Formulation 3
  • US10925871 Vuln 50 2035-02-25
    This patent protects stable oral pharmaceutical compositions of sitagliptin base and processes for their preparation.
  • US10925871 Vuln 50 2035-02-25
    This patent protects stable oral pharmaceutical compositions of sitagliptin base and processes for their preparation.
  • US10925871 Vuln 50 2035-02-25
    This patent protects stable oral pharmaceutical compositions of sitagliptin base and processes for their preparation.

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Formulation 3 patents

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track Zydus Lifesciences's patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export